Next-generation sequencing: FDA offers guidance to streamline path to market

The FDA on Thursday finalized two guidance documents related to next-generation sequencing (NGS) and drafted new guidance on investigational in vitro diagnostics (IVDs) in oncology trials – all of which offer recommendations to provide test developers with a more efficient path to market.